Physician profile
Brian D Wright
NPI 1770057788
$1,309.81
in general payments reported to CMS, 2019-2025
12 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2023: $505 · 2024: $547 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.50 |
| Education | $190.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $304.75 | 2021-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $259.98 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $185.51 | 2021-2024 | Invega Sustenna, Spravato |
| Alkermes, INC. | $119.78 | 2023 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.76 | 2023-2024 | Caplyta |
| Lundbeck LLC | $102.94 | 2021-2024 | Rexulti |
| Brainsway USA INC | $80.43 | 2023 | |
| Idorsia Pharmaceuticals US INC | $38.55 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $35.00 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $34.42 | 2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $18.86 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.